AbbVie Inc. (NYSE:ABBV) Shares Purchased by Liberty Capital Management Inc.

Liberty Capital Management Inc. boosted its stake in AbbVie Inc. (NYSE:ABBV) by 0.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 39,251 shares of the company’s stock after buying an additional 103 shares during the period. AbbVie makes up approximately 1.5% of Liberty Capital Management Inc.’s portfolio, making the stock its 18th biggest position. Liberty Capital Management Inc.’s holdings in AbbVie were worth $6,975,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. AMF Tjanstepension AB purchased a new stake in AbbVie during the third quarter worth about $8,777,000. Fiduciary Financial Group LLC purchased a new stake in AbbVie during the 3rd quarter worth approximately $283,000. Montis Financial LLC acquired a new stake in AbbVie during the 3rd quarter worth approximately $522,000. Cardinal Capital Management Inc. boosted its position in AbbVie by 0.3% in the 3rd quarter. Cardinal Capital Management Inc. now owns 197,427 shares of the company’s stock valued at $38,988,000 after buying an additional 588 shares during the period. Finally, Carnegie Investment Counsel grew its stake in shares of AbbVie by 3.4% in the third quarter. Carnegie Investment Counsel now owns 38,431 shares of the company’s stock worth $7,589,000 after acquiring an additional 1,252 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several analyst reports. Leerink Partnrs upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Morgan Stanley increased their price target on AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Argus raised AbbVie from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. Citigroup raised their target price on shares of AbbVie from $205.00 to $215.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Piper Sandler boosted their price target on shares of AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $208.35.

AbbVie Price Performance

ABBV stock opened at $190.67 on Monday. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64. The company has a market capitalization of $336.94 billion, a P/E ratio of 79.45, a PEG ratio of 1.53 and a beta of 0.58. The business has a 50 day simple moving average of $177.54 and a 200-day simple moving average of $185.69. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same quarter last year, the firm posted $2.79 EPS. As a group, equities analysts anticipate that AbbVie Inc. will post 12.32 EPS for the current year.

Insider Buying and Selling

In related news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.25% of the company’s stock.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.